Re: Darolutamide in Nonmetastatic Castration-Resistant Prostate Cancer Fizazi K, Shore N, Tammela TL, et al N Engl J Med 2019;380:1235-46

Alghazo Omar; Thangasamy Isaac; Sathianathen Niranjan; Murphy Declan G.

首页> 外文期刊>European urology >Re: Darolutamide in Nonmetastatic Castration-Resistant Prostate Cancer Fizazi K, Shore N, Tammela TL, et al N Engl J Med 2019;380:1235-46

【24h】

Re: Darolutamide in Nonmetastatic Castration-Resistant Prostate Cancer Fizazi K, Shore N, Tammela TL, et al N Engl J Med 2019;380:1235-46

机译：Re：Darolutamide在非容性阉割前列腺癌中癌症Fizazi K，Shore N，Tammela TL，等，Negl J Med 2019; 380：1235-46

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《European urology》 |2019年第4期|共3页
作者
Alghazo Omar; Thangasamy Isaac; Sathianathen Niranjan; Murphy Declan G.;
展开▼
作者单位

Univ Melbourne Peter MacCallum Canc Ctr Div Canc Surg Melbourne Vic Australia;

Univ Melbourne Peter MacCallum Canc Ctr Div Canc Surg Melbourne Vic Australia;

Univ Melbourne Peter MacCallum Canc Ctr Div Canc Surg Melbourne Vic Australia;

Univ Melbourne Peter MacCallum Canc Ctr Div Canc Surg Melbourne Vic Australia;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类泌尿科学（泌尿生殖系疾病）;
关键词

相似文献

外文文献
专利

1. Re: Darolutamide in Nonmetastatic Castration-Resistant Prostate Cancer Fizazi K, Shore N, Tammela TL, et al N Engl J Med 2019;380:1235-46 [J] . Alghazo Omar, Thangasamy Isaac, Sathianathen Niranjan, European urology . 2019,第4期

机译：Re：Darolutamide在非容性阉割前列腺癌中癌症Fizazi K，Shore N，Tammela TL，等，Negl J Med 2019; 380：1235-46
2. Re: Joaquin Mateo, Karim Fizazi, Silke Gillessen, et al. Managing Nonmetastatic Castration-resistant Prostate Cancer. Eur Urol 2019;75:285-93 [J] . Rocco Bernardo, Sighinolfi Maria Chiara European urology . 2020,第3期

机译：Re：Joaquin Mateo，Karim Fizazi，Silke Gillessen，等。管理非容性阉割的前列腺癌。 EUR UROL 2019; 75：285-93
3. Re: Joaquin Mateo, Karim Fizazi, Silke Gillessen, et al. Managing Nonmetastatic Castration-resistant Prostate Cancer. Eur Urol 2019:75:285-93 [J] . von Eyben Finn Edler, Bauman Glenn European urology . 2020,第3期

机译：Re：Joaquin Mateo，Karim Fizazi，Silke Gillessen，等。管理非容性阉割的前列腺癌。 EUR UROL 2019：75：285-93
4. Castration-Resistant Prostate Cancer: Novel Targets, Agents, and Trials [C] . Evan Y. Yu Genitourinary Cancers Symposium . 2012

机译：抗阉割前列腺癌：新型靶点，药剂和试验
5. Muscle Cross-Sectional Area Is Improved and Physical Funciton Is Maintained After Home-Based Exercise in Men with Metastatic Castration-Resistant Prostate Cancer Undergoing Androgen Deprivation Therapy [D] . Alzer, Mohamdod Saber. 2020

机译：改善肌横截面积，并且在具有转移阉割的前列腺癌接受雄激素剥夺治疗的男性中的男性锻炼之后，将物理静脉凝集维持
6. Evaluation of Clinically Relevant Drug–Drug Interactions and Population Pharmacokinetics of Darolutamide in Patients with Nonmetastatic Castration-Resistant Prostate Cancer: Results of Pre-Specified and Post Hoc Analyses of the Phase III ARAMIS Trial [O] . Neal Shore, Christian Zurth, Robert Fricke, -1

机译：评价非转移性去势抵抗性前列腺癌患者中临床相关的药物相互作用和达洛鲁胺的群体药代动力学：III期ARAMIS试验的预先和事后分析结果
7. Evaluation of Clinically Relevant Drug–Drug Interactions and Population Pharmacokinetics of Darolutamide in Patients with Nonmetastatic Castration-Resistant Prostate Cancer: Results of Pre-Specified and Post Hoc Analyses of the Phase III ARAMIS Trial [O] . Neal Shore, Christian Zurth, Robert Fricke, 2019

机译：临床相关药物 - 药物相互作用和达利氟酰胺患者抗性前列腺癌患者的药代动力学评价：III期阿拉米斯试验的预先指定和后HOC分析的结果

Re: Darolutamide in Nonmetastatic Castration-Resistant Prostate Cancer Fizazi K, Shore N, Tammela TL, et al N Engl J Med 2019;380:1235-46

著录项

相似文献

相关主题

期刊订阅